8-K: Humana Revises 2024 EPS Guidance Downward Despite Membership Growth

Humana reported second quarter earnings, revised its full-year GAAP EPS guidance downward, but affirmed its adjusted EPS guidance and increased its Medicare Advantage membership growth forecast.

Summary

• Humana reported second quarter 2024 earnings with a GAAP EPS of $5.62 and an adjusted EPS of $6.96.
• Year-to-date 2024, Humana's GAAP EPS is $11.74 and adjusted EPS is $14.19.
• The company revised its full-year 2024 GAAP EPS guidance to approximately $12.81, down from the previous guidance of approximately $13.93.
• Humana affirmed its full-year 2024 adjusted EPS guidance of approximately $16.00.
• The company also affirmed its full-year 2024 insurance segment benefit ratio guidance of approximately 90 percent.
• Humana raised its 2024 individual Medicare Advantage annual membership growth forecast by 75,000, now anticipating approximately 225,000 new members, or 4.2 percent growth.
• Second quarter results were driven by higher than anticipated member risk scores, favorable claims development and lower than planned administrative expenses.
• These positive factors were partially offset by higher net inpatient costs.
• Humana expects the percentage of full year earnings recognized in the third quarter will be in the low 20s.
• The company anticipates a 30-basis point year over year reduction in the adjusted consolidated operating cost ratio in 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong membership growth and adjusted EPS exceeding expectations, but tempered by the downward revision of GAAP EPS guidance and concerns about rising inpatient costs and the 2025 outlook.

Positives

• Humana's second quarter adjusted EPS exceeded expectations due to higher revenue, favorable claims development, and lower administrative expenses.
• The company is experiencing strong growth in its Medicare Advantage membership, leading to an increased full-year growth forecast.
• Humana is making progress in expanding its CenterWell Primary Care business, with significant patient growth and new clinic locations planned.
• The company is successfully growing its Medicaid platform, with new contracts in Oklahoma and Indiana.
• Humana is focused on driving organizational efficiencies and productivity gains, expecting a reduction in the adjusted consolidated operating cost ratio.
• Humana is leveraging technology through partnerships with Google Cloud and Healthpilot to improve efficiency and customer experience.
• Humana's value-based care arrangements have resulted in significant medical cost savings compared to Fee-for-Service Medicare.

Negatives

• Humana revised its full-year 2024 GAAP EPS guidance downward from approximately $13.93 to approximately $12.81.
• The company experienced higher than anticipated inpatient admissions and net inpatient costs in the second quarter.
• Humana anticipates a decline of a few hundred thousand individual MA members in 2025 due to plan and county exits.
• The company has seen modestly higher claim costs in newly implemented Medicaid states.
• The external environment has been challenging, with a rate environment that has not kept pace with accelerated medical cost trends.

Risks

• Humana's profitability could be adversely affected if it does not design and price its products properly.
• The company's reserves may be insufficient due to the variability in claim payment patterns and medical cost trends.
• Failure to effectively implement operational and strategic initiatives, including Medicare initiatives, could negatively impact the business.
• Cybersecurity attacks and data breaches could disrupt operations and lead to the dissemination of sensitive information.
• Legal actions and disputes could result in substantial monetary damages or changes in business practices.
• Changes to the risk-adjustment model utilized by CMS could have a material adverse effect on the company's operating results.
• New laws or regulations could increase the company's cost of doing business.
• Failure to manage acquisitions and divestitures successfully may have a material adverse effect on the company's results.
• The company faces significant competition in attracting and retaining talented employees.
• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana's financial performance.

Future Outlook

Humana anticipates margin expansion and adjusted EPS growth in 2025, despite a decline in individual MA members due to plan and county exits. The company is focused on driving growth and productivity to support sustainable earnings growth. Humana will provide a further update on its 2025 outlook on its third quarter earnings call.

Management Comments

• Jim Rechtin, President and CEO, stated that Humana offers a strong value proposition to customers and investors.
• Jim Rechtin mentioned that Humana has opportunities to improve in product and pricing, technology deployment, operating discipline, and multi-year planning.
• Jim Rechtin expressed confidence in Humana's ability to deliver high-quality care and consumer value at a lower cost than Fee-for-Service Medicare.
• Susan Diamond, CFO, noted that second quarter financial results exceeded expectations.
• Management reaffirmed the 2024 adjusted EPS outlook of approximately $16.00 and full year insurance segment benefit ratio guidance of approximately 90 percent.

Industry Context

Humana's results are being released amidst a dynamic healthcare environment with increasing medical costs and regulatory changes. The company's focus on value-based care and technology adoption aligns with broader industry trends aimed at improving outcomes and reducing costs. The company is also navigating the challenges of the Medicare Advantage rate environment and the redetermination process in Medicaid.

Comparison to Industry Standards

• Humana's Medicare Advantage membership growth of 4.2% is a positive sign, but it is important to compare this to the growth rates of competitors like UnitedHealth Group and CVS Health (Aetna) to assess its relative performance.
• The company's benefit ratio of approximately 90% is a key metric to watch, as it reflects the cost of healthcare services. It should be compared to the benefit ratios of other major health insurers to determine if Humana is managing costs effectively.
• Humana's focus on value-based care is in line with industry trends, but the actual savings of 23.2% in medical costs compared to Fee-for-Service Medicare should be benchmarked against similar programs at other companies to evaluate its effectiveness.
• The company's plan to open 23 senior-focused primary care centers at Walmart locations is a unique strategy that could provide a competitive advantage, but its success will depend on execution and patient adoption.
• Humana's adjusted EPS guidance of approximately $16.00 should be compared to the earnings forecasts of other major health insurers to assess its relative profitability.
• The company's debt-to-total capitalization ratio of 43.6% is a key indicator of financial health and should be compared to the leverage ratios of its peers to assess its risk profile.

Stakeholder Impact

• Shareholders may experience mixed reactions due to the downward revision of GAAP EPS guidance, but the affirmation of adjusted EPS guidance and increased membership growth may be viewed positively.
• Employees may be impacted by the company's focus on organizational efficiencies and productivity gains.
• Customers may benefit from the company's focus on value-based care and technology adoption, which could lead to better health outcomes and lower costs.
• Suppliers and providers may be impacted by the company's efforts to manage medical costs and expand its value-based care arrangements.
• Creditors may be impacted by the company's debt-to-total capitalization ratio and its ability to generate cash flow.

Next Steps

• Humana will continue to assess the durability of higher inpatient admissions and implement mitigation activities.
• The company will focus on clinical and trend management initiatives, including value-based arrangements.
• Humana will continue to expand its CenterWell Primary Care footprint, including the new Walmart locations.
• The company will continue to invest in its Medicaid platform and work with state partners to address emerging cost trends.
• Humana will host an Investor Day in the first half of next year to provide updates on its progress.
• The company will provide a further update on its 2025 outlook on its third quarter earnings call.

Key Dates

Keywords

Medicare Advantage, Medicaid, CenterWell, EPS, Healthcare, Insurance, Membership Growth, Benefit Ratio, Operating Cost Ratio, Primary Care